Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (301-310 of 352) with videos related to

Pageof 36
Sort By:
Journal of Crohn'S & Colitis|February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential SolutionsMathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Plos One|June 9, 2015
Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver AgreementBindia Jharap, Dirk P van Asseldonk, Nanne K H de Boer, et al.
Plos One|February 18, 2009
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's diseaseMaureen J Koslowski, Irmgard Kübler, Mathias Chamaillard, et al.
Journal of Crohn'S & Colitis|November 7, 2012
Clinical presentation of venous thromboembolism in inflammatory bowel diseasePavol Papay, Wolfgang Miehsler, Herbert Tilg, et al.
Annals of the Rheumatic Diseases|May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Remo Panaccione, Brian G Feagan, et al.
Gastroenterology|March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseStefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.
The American Journal of Gastroenterology|December 6, 2012
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion processLaurent Peyrin-Biroulet, Vincent Billioud, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Ebiomedicine|September 6, 2023
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formationErika Garner-Spitzer, Angelika Wagner, Venugopal Gudipati, et al.
Pageof 36

Showing results (301-310 of 352) with videos related to

Sort By:
Pageof 36
Journal of Crohn'S & Colitis|February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential SolutionsMathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Plos One|June 9, 2015
Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver AgreementBindia Jharap, Dirk P van Asseldonk, Nanne K H de Boer, et al.
Plos One|February 18, 2009
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's diseaseMaureen J Koslowski, Irmgard Kübler, Mathias Chamaillard, et al.
Journal of Crohn'S & Colitis|November 7, 2012
Clinical presentation of venous thromboembolism in inflammatory bowel diseasePavol Papay, Wolfgang Miehsler, Herbert Tilg, et al.
Annals of the Rheumatic Diseases|May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Remo Panaccione, Brian G Feagan, et al.
Gastroenterology|March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseStefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.
The American Journal of Gastroenterology|December 6, 2012
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion processLaurent Peyrin-Biroulet, Vincent Billioud, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Ebiomedicine|September 6, 2023
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formationErika Garner-Spitzer, Angelika Wagner, Venugopal Gudipati, et al.
Pageof 36